Rhythm Pharmaceuticals, Inc.
RYTM
Kedudukan dalam Saham
#2937
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Harga Saham
$89.83
Modal Pasaran
$6.18B
Perubahan (1 hari)
1.81%
Perubahan (1 tahun)
-20.07%
Negara
US
Perdagangan Rhythm Pharmaceuticals, Inc. (RYTM)
Kategori
Healthcare
Nisbah P/E bagi Rhythm Pharmaceuticals, Inc. (RYTM)
Nisbah P/E pada October 2026 TTM: -27.88
Menurut laporan kewangan dan harga saham terkini Rhythm Pharmaceuticals, Inc., nisbah P/E semasa (TTM) ialah -27.88. Pada akhir 2023, syarikat mempunyai nisbah P/E sebanyak -14.36.
Sejarah nisbah P/E bagi Rhythm Pharmaceuticals, Inc. dari 2012 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | -27.88 | 112.83% |
| 2024 | -13.10 | -8.73% |
| 2023 | -14.36 | 71.31% |
| 2022 | -8.38 | 17.84% |
| 2021 | -7.11 | -29.14% |
| 2020 | -10.04 | 61.55% |
| 2019 | -6.21 | -44.80% |
| 2018 | -11.25 | -51.17% |
| 2017 | -23.04 | 18.79% |
| 2016 | -19.40 | -29.78% |
| 2015 | -27.62 | -41.36% |
| 2014 | -47.11 | -33.05% |
| 2013 | -70.37 | -15.40% |
| 2012 | -83.18 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 28.78 | -203.23% |
US
|
|
| -28.36 | 1.71% |
US
|
|
| -24.57 | -11.89% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -208.78% |
NL
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.